Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Estée Lauder Sues Jo Malone Over Trademark Dispute Involving Zara 
Bolsonaro Hospitalized in ICU with Bronchopneumonia Amid Calls for House Arrest 
xAI Faces Federal Lawsuit Over Grok AI-Generated Child Sexual Abuse Material 
U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising 
Trump Administration Settles Lawsuit Barring Federal Agencies from Pressuring Social Media Censorship 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Federal Judge Blocks Pentagon's Restrictive Press Access Policy 
Federal Judge Blocks Trump Administration's Move to End Temporary Protected Status for Somali Immigrants 
The Missouri Supreme Court rejected Johnson & Johnson's appeal of a ruling by the Missouri Court of Appeals awarding $2.12 billion damages to women who blamed the company's asbestos-tainted products for their ovarian cancer.
The New Brunswick, New Jersey-based firm called the verdict a product of fundamentally flawed trial, grounded in a faulty presentation of the facts and vowed to elevate the case to the US Supreme Court.
Johnson & Johnson insists that there were decades of independent scientific evaluations that found their product safe, asbestos-free, and not cancer-causing.
In July 2018, a jury ruled that Johnson & Johnson was liable $4.69 billion to the complainants.
The Missouri Court of Appeals upheld the jury verdict on June 23 but reduced the payout to $2.12 billion after dismissing claims by 22 plaintiffs.
It said that it may be inferred from evidence that the company disregarded consumer safety for profit.
Kevin Parker, a lawyer for the plaintiffs, said that Johnson & Johnson should accept the verdict of the jury and the appellate court and compensate the victims.
Johnson & Johnson said it would set aside a $2.1 billion reserve for the verdict.
The company, which said that it would stop selling its Baby Powder talc in the US and Canada, revealed that it faces over 21,800 lawsuits claiming that its talc products contain asbestos, a known carcinogen.
Johnson & Johnson's baby powder was intensely scrutinized for safety after a 2018 Reuters investigative report said that it knew for decades that about the asbestos contamination of its talc.
Evidence showed that from at least 1971 to the early 2000s,
Johnson & Johnson's raw talc and finished powders have tested positive for small amounts of asbestos.
